BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

617 related articles for article (PubMed ID: 18158041)

  • 1. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
    Spiess PE; Tannir NM; Brown GA; Liu P; Tu SM; Evans JG; Pisters LL
    Urology; 2007 Dec; 70(6):1173-8. PubMed ID: 18158041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
    Spiess PE; Tannir NM; Tu SM; Brown GA; Liu P; Kamat AM; Wood CG; Evans JG; Pisters LL
    Cancer; 2007 Dec; 110(12):2700-8. PubMed ID: 17948916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
    Spiess PE; Brown GA; Pisters LL; Liu P; Tu SM; Evans JG; Kamat AM; Black P; Tannir NM
    Cancer; 2006 Oct; 107(7):1503-10. PubMed ID: 16944534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer.
    Spiess PE; Brown GA; Liu P; Tannir NM; Tu SM; Evans JG; Czerniak B; Kamat AM; Pisters LL
    Cancer; 2006 Oct; 107(7):1483-90. PubMed ID: 16944541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcome following post-chemotherapy retroperitoneal lymph node dissection in men with intermediate- and poor-risk nonseminomatous germ cell tumour.
    Shayegan B; Carver BS; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    BJU Int; 2007 May; 99(5):993-7. PubMed ID: 17437432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
    Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
    Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term clinical outcome after postchemotherapy retroperitoneal lymph node dissection in men with residual teratoma.
    Carver BS; Shayegan B; Serio A; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Mar; 25(9):1033-7. PubMed ID: 17261854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection.
    Svatek RS; Spiess PE; Sundi D; Tu SM; Tannir NM; Brown GA; Kamat AM; Wood CG; Pisters LL
    Cancer; 2009 Mar; 115(6):1310-7. PubMed ID: 19156903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postchemotherapy retroperitoneal lymph node dissection is effective therapy in selected patients with elevated tumor markers after primary chemotherapy alone.
    Coogan CL; Foster RS; Rowland RG; Bihrle R; Smith ER; Einhorn LH; Roth BJ; Donohue JP
    Urology; 1997 Dec; 50(6):957-62. PubMed ID: 9426730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The indication for postchemotherapy lymph node dissection in clinical stage IS nonseminomatous germ cell tumor.
    Dash A; Carver BS; Stasi J; Bajorin DF; Motzer RJ; Bosl GJ; Sheinfeld J
    Cancer; 2008 Feb; 112(4):800-5. PubMed ID: 18172902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repeat retroperitoneal lymph-node dissection after chemotherapy for metastatic testicular germ cell tumour.
    Willis SF; Winkler M; Savage P; Seckl MJ; Christmas TJ
    BJU Int; 2007 Oct; 100(4):809-12. PubMed ID: 17711512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is full bilateral retroperitoneal lymph node dissection always necessary for postchemotherapy residual tumor?
    Beck SD; Foster RS; Bihrle R; Donohue JP; Einhorn LH
    Cancer; 2007 Sep; 110(6):1235-40. PubMed ID: 17665498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incidence of metastatic nonseminomatous germ cell tumor outside the boundaries of a modified postchemotherapy retroperitoneal lymph node dissection.
    Carver BS; Shayegan B; Eggener S; Stasi J; Motzer RJ; Bosl GJ; Sheinfeld J
    J Clin Oncol; 2007 Oct; 25(28):4365-9. PubMed ID: 17906201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonrandomized comparison of primary chemotherapy and retroperitoneal lymph node dissection for clinical stage IIA and IIB nonseminomatous germ cell testicular cancer.
    Stephenson AJ; Bosl GJ; Motzer RJ; Bajorin DF; Stasi JP; Sheinfeld J
    J Clin Oncol; 2007 Dec; 25(35):5597-602. PubMed ID: 18065732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contemporary management of postchemotherapy testis cancer.
    Daneshmand S; Albers P; Fosså SD; Heidenreich A; Kollmannsberger C; Krege S; Nichols C; Oldenburg J; Wood L
    Eur Urol; 2012 Nov; 62(5):867-76. PubMed ID: 22938868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of primary tumor size and preorchiectomy serum tumor marker level in predicting pathologic stage at retroperitoneal lymph node dissection in clinical Stage A nonseminomatous germ cell tumors.
    Beck SD; Foster RS; Bihrle R; Donohue JP
    Urology; 2007 Mar; 69(3):557-9. PubMed ID: 17382165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
    Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
    BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection.
    Spiess PE; Brown GA; Liu P; Tu SM; Tannir NM; Evans JG; Kamat AM; Kassouf W; Pisters LL
    J Urol; 2007 Jan; 177(1):131-8. PubMed ID: 17162023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimizing treatment without compromising cure with primary surveillance for clinical stage I embryonal predominant nonseminomatous testicular cancer: a population based analysis from British Columbia.
    Al-Tourah AJ; Murray N; Coppin C; Kollmannsberger C; Man A; Chi KN
    J Urol; 2005 Dec; 174(6):2209-13, discussion 2213. PubMed ID: 16280765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome analysis for patients with elevated serum tumor markers at postchemotherapy retroperitoneal lymph node dissection.
    Beck SD; Foster RS; Bihrle R; Einhorn LH; Donohue JP
    J Clin Oncol; 2005 Sep; 23(25):6149-56. PubMed ID: 16135481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.